
Amyl Therapeutics bags €11m Series A extension
Amyl Therapeutics SA has secured €5m Series A extension from long-term investors Merieux Equity Partners and Noshaq, together with Mr Evren Ucok as a...

microRNA could offer a safe target in atherosclerosis
The researcher demonstrateded that targeting of miR-206-3p with an experimental compound safely reversed the onset of atherosclerosis in a...

French team BioAroma awarded with BISC-E 2023 prize
In front of around 200 invited guests, the French team received the cash prize for first place in the BISC-E 2023 competition and a one-year free BIC...

BioNtech reports Car-T/mRNA booster study results at ESMO
Testing different dose levels of its adoptive cell therapy BNT.221-01, a combination of Claudin 6 (CLDN6)-targeted Car-T cells (derived from...

CEPI commits up to US$80m to University of Oxford to develop vaccines
The US$80m strategic partnership of CEPI, which was established in 2016 in the wake of the Ebola virus outbreak in west Africa, the University of...

Mithra raises €20m through private placement
Under the terms of the Private Placement, Armistice Capital committed to subscribe for 10 million new shares atz a share price of 2€ per share , of...

Alfasigma SpA set to take over Galapagos programme
Under the planned agreement, Alfasigma SpA will pay €50m upfront, milestones totaling €120m and mid-single to mid-double digit royalties on European...